Abstract
Experiments on labeling of diclofenac, an anti-inflammatory drug, with 99mTc were performed. High (about 96%) yield of 99mTc-diclofenac is reached under the following conditions: 50 μg of Sn(II), 100 μg of the substrate, 30 min, pH 7. 99mTc-diclofenac was stable for 4 h. Biological distribution of 99mTc-diclofenac was investigated in mice bearing inflammations experimentally induced in the left thigh by Escherichia coli (bacterial infection model) and turpentine oil (sterile inflammation model). The uptake ratio in the inflamed and contralateral thighs (target-to-nontarget, T/NT) was evaluated. In the case of bacterial infection, the T/NT ratio only slightly exceeds unity, whereas in the case of sterile inflammation it reaches 4.46 ± 0.07 in 2 h. Thus, 99mTc-diclofenac allows differentiation between septic and aseptic inflammation and can be recommended for further clinical trials.
Similar content being viewed by others
References
Motaleb, M.A., Attallah, K.M., El-Kolaly, M.T., and Abd El-Bary, A., Arab J. Nucl. Sci. Appl., 2007, vol. 40, no. 2, p. 91.
Motaleb, M.A., Attallah, K.M., El-Kolaly, M.T., and Abd El-Bary, A., Arab J. Nucl. Sci. Appl., 2007, vol. 40, no. 1, p. 27.
Arginelli, D., Heikkonen, J., Miranti, A., et al., J. Radioanal. Nucl. Chem., 2009, vol. 282, no. 1, p. 281.
Robinson, R.G., Spicear, J.A., and Preston, D.F., Med. Biol., 1987, vol. 4, p. 219.
Ridone, S., Arginelli, D., Inglese, E., et al., J. Radioanal. Nucl. Chem., 2009, vol. 282, no. 1, p. 287.
Ibrahim, I.T., J. Radioanal. Nucl. Chem., 2009, vol. 281, no. 3, p. 669.
El-Shahawi, M.S., El-Shaboury, G., Aly, M.A.M., and El-Tawoosy, M., J. Anal. Sci. (Jpn.), 2003, vol. 19, p. 1.
Rennen, H.J.M., Boerman, O.C., Oyen, W.J.G., and Corstens, F.H.M., Med. Chem. Rev., 2004, vol. 1, pp. 27–30.
Das, S.S., Hall, A.V., Wareham, D.D.W., and Britton, K.E., Braz. Arch. Biol. Technol., 2002, vol. 45, p. 25.
Lupetti, A., Welling, M.M., Paulwels, E.K.J., and Nibbering, P.H., Lancet Infect. Dis., 2003, vol. 3, pp. 223–226.
Welling, M.M., Lupetti, A., Balter, H.S., et al., J. Nucl. Med., 2001, vol. 42, no. 5, pp. 788–790.
Seabold, J.E., Palestro, C.J., and Brown, M.L., J. Nucl. Med., 1997, vol. 38, pp. 994–997.
Seabold, J.E., Forstrom, L.A., and Schauwecher, D.S., J. Nucl. Med., 1997, vol. 38, pp. 997–999.
Schrijver, M.D., Streule, K., and Senekowitsch, R., Nucl. Med. Commun., 1987, vol. 8, pp. 895–897.
Buscombe, J.R., Miller, R.F., and Lui, D., Nucl. Med. Commun., 1991, vol. 12, pp. 583–587.
McAfee, J.G., Gagne, G., and Subramanian, G., J. Nucl. Med., 1991, vol. 32, p. 2126.
Akhtar, M.S., Qaisar, A., and Irfanullah, J., J. Nucl. Med., 2005, vol. 46, pp. 567–568.
Akhtar, M.S., Iqbal, J., and Khan, M.A., J. Nucl. Med., 2004, vol. 45, pp. 849–851.
Nibbering, P.H., Welling, M.M., and Paulusma-Annema, A., J. Nucl. Med., 2004, vol. 45, pp. 321–325.
Rennen, H.J., Boerman, O.C., Oyen, W.J., and Corstens, F.H., Eur. J. Nucl. Med., 2001, vol. 28, pp. 241–244.
Boerman, O.C., Laverman, P., Oyen, W.J., et al., Prog. Lipid Res., 2000, vol. 39, pp. 461–463.
Erdogan, S., Ozer, A.Y., Ercan, M.T., and Hincal, A.A., J. Microencapsul., 2000, vol. 17, pp. 459–461.
Singh, A.K., Verma, J., Bhatnagar, A., and Ali, A.W., J. Nucl. Med., 2003, vol. 2, pp. 103–106.
Martin-Comin, J., Soroa, V., Rabiller, G., et al., Rev. Esp. Med. Nucl., 2004, vol. 23, pp. 357–358.
Gomes Barreto, V., Rabiller, G., Iglesias, F., et al., Rev. Esp. Med. Nucl., 2005, vol. 24, pp. 312–315.
Motaleb, M.A., J. Radioanal. Nucl. Chem., 2007, vol. 272, pp. 95–97.
Robbins, P.J., Chromatography of Technetium-99m Radiopharmaceuticals, a Practical Guide, New York: US Society of Nuclear Medicine, 1984, p. 51.
Motaleb, M.A., Synthesis and evaluation of some 99mTccomplexes applied in nuclear medicine, PhD Thesis, Faculty of Science, Ain-Shams Univ., 2001, p. 25.
Boyd, R.E., J. Nucl. Spectrum Aust., 1986, vol. 2, no. 1, p. 18.
Svoboda, K., Lezama, J., and Melichor, F., J. Radioanal. Nucl. Chem., 1985, vol. 96, p. 405.
Laken, V., Boerman, C.J., Oyen, O.C., et al., J. Nucl. Med., 2000, vol. 41, pp. 463–469.
Oyen, W.J.G., Boerman, O.C., and Corstens, F.H.M., J. Microbiol. Meth., 2001, vol. 47, pp. 151–157.
Mostafa, M., Motaleb, M.A., and Sakr, T.M., Appl. Radiat. Isot., 2010, vol. 68, pp. 1959–1963.
Motaleb, M.A., Alabdullah, E.S., and Zaghary, W.A., J. Radioanal. Nucl. Chem., 2011, vol. 287, pp. 61–67.
Al-Wabli, R.I., Motaleb, M.A., Kadi, A.A., et al., J. Radioanal. Nucl. Chem., 2011, vol. 290, no. 2, pp. 507–513.
Asikoglu, M., Yurt, F., Cagliyan, O., et al., Appl. Radiat. Isot., 2000, vol. 53, pp. 411–413.
Johannsen, B. and Spies, B., Chemistry and radiopharmacology of technetium complexes, Workshop on Generator and Cyclotron Produced Radiopharmaceuticals, Riyad (Saudi Arabia), Oct. 13–31, 1991.
Abd El-Ghany, E.A., Studies on the preparation of lyophilized radiopharmaceutical kits and their evaluation, MSc Thesis, Faculty of Pharmacy, Cairo Univ., 1998, p. 71.
Cheng, C.H., Meares, C.F., and Goodwin, D.A., Application of Nuclear and Radiochemistry, Lambrecht, R.M. and Morcos, N., Eds., New York: Pergamon, 1983, p. 103.
Thorell, J.O., Stone-Elander, S., Ingvar, M., and Eriksson, L., J. Label. Compd. Radiopharm., 1994, vol. 36, p. 251.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Russian in Radiokhimiya, 2014, Vol. 56, No. 6, pp. 531–535.
The text was submitted by the authors in English.
Rights and permissions
About this article
Cite this article
El-Tawoosy, M., Mahmoud, A.F. & Soliman, S.E. Preparation and preclinical evaluation of 99mTc-diclofenac as a model for inflammation imaging. Radiochemistry 56, 622–627 (2014). https://doi.org/10.1134/S1066362214060071
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1066362214060071